Approach to relapsed refractory myeloma

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Despite tremendous advances in the initial management of patients with myeloma, now translating to at least a doubling of median overall survival in the last decade, this disease remains incurable in nearly all patients [1]. Although time to first relapse has been extended with superior induction, consolidation, and maintenance strategies, relapse is inevitable. With the emergence of many novel agents in the relapsed setting, options for providers and patients have dramatically increased. The optimal sequencing, combination, and dosing of these agents have yet to be determined. Indeed, with so many therapeutic options available, the clinician must have a rational, risk stratified and feasible to approaching patients in relapse. This chapter provides an approach to therapy for the myeloma patient with relapsed and/or refractory disease. The detailed discussion of the data for the various treatment options in relapsed disease, including Stem Cell Transplantation, New Agents, and Biologic Therapy, is covered in subsequent chapters (see Chaps. 10–13). The purpose of this chapter is to provide an overall strategy for the management of relapsed refractory disease and to help guide clinicians in selecting the most appropriate therapy for their patient. This approach emphasizes the heterogeneity of both the disease and the patient.

Original languageEnglish (US)
Title of host publicationMultiple Myeloma: Diagnosis and Treatment
PublisherSpringer New York
Pages95-100
Number of pages6
ISBN (Print)9781461485209, 9781461485193
DOIs
StatePublished - Jan 1 2014

Fingerprint

Recurrence
Biological Therapy
Stem Cell Transplantation
Therapeutics
Maintenance
Survival

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Mikhael, J. R., Kumar, S. K., & Rajkumar, S. V. (2014). Approach to relapsed refractory myeloma. In Multiple Myeloma: Diagnosis and Treatment (pp. 95-100). Springer New York. https://doi.org/10.1007/978-1-4614-8520-9_9

Approach to relapsed refractory myeloma. / Mikhael, Joseph R; Kumar, Shaji K; Rajkumar, S Vincent.

Multiple Myeloma: Diagnosis and Treatment. Springer New York, 2014. p. 95-100.

Research output: Chapter in Book/Report/Conference proceedingChapter

Mikhael, JR, Kumar, SK & Rajkumar, SV 2014, Approach to relapsed refractory myeloma. in Multiple Myeloma: Diagnosis and Treatment. Springer New York, pp. 95-100. https://doi.org/10.1007/978-1-4614-8520-9_9
Mikhael JR, Kumar SK, Rajkumar SV. Approach to relapsed refractory myeloma. In Multiple Myeloma: Diagnosis and Treatment. Springer New York. 2014. p. 95-100 https://doi.org/10.1007/978-1-4614-8520-9_9
Mikhael, Joseph R ; Kumar, Shaji K ; Rajkumar, S Vincent. / Approach to relapsed refractory myeloma. Multiple Myeloma: Diagnosis and Treatment. Springer New York, 2014. pp. 95-100
@inbook{d9ab750fa0b847cebf8fe65c7bf2c871,
title = "Approach to relapsed refractory myeloma",
abstract = "Despite tremendous advances in the initial management of patients with myeloma, now translating to at least a doubling of median overall survival in the last decade, this disease remains incurable in nearly all patients [1]. Although time to first relapse has been extended with superior induction, consolidation, and maintenance strategies, relapse is inevitable. With the emergence of many novel agents in the relapsed setting, options for providers and patients have dramatically increased. The optimal sequencing, combination, and dosing of these agents have yet to be determined. Indeed, with so many therapeutic options available, the clinician must have a rational, risk stratified and feasible to approaching patients in relapse. This chapter provides an approach to therapy for the myeloma patient with relapsed and/or refractory disease. The detailed discussion of the data for the various treatment options in relapsed disease, including Stem Cell Transplantation, New Agents, and Biologic Therapy, is covered in subsequent chapters (see Chaps. 10–13). The purpose of this chapter is to provide an overall strategy for the management of relapsed refractory disease and to help guide clinicians in selecting the most appropriate therapy for their patient. This approach emphasizes the heterogeneity of both the disease and the patient.",
author = "Mikhael, {Joseph R} and Kumar, {Shaji K} and Rajkumar, {S Vincent}",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/978-1-4614-8520-9_9",
language = "English (US)",
isbn = "9781461485209",
pages = "95--100",
booktitle = "Multiple Myeloma: Diagnosis and Treatment",
publisher = "Springer New York",

}

TY - CHAP

T1 - Approach to relapsed refractory myeloma

AU - Mikhael, Joseph R

AU - Kumar, Shaji K

AU - Rajkumar, S Vincent

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Despite tremendous advances in the initial management of patients with myeloma, now translating to at least a doubling of median overall survival in the last decade, this disease remains incurable in nearly all patients [1]. Although time to first relapse has been extended with superior induction, consolidation, and maintenance strategies, relapse is inevitable. With the emergence of many novel agents in the relapsed setting, options for providers and patients have dramatically increased. The optimal sequencing, combination, and dosing of these agents have yet to be determined. Indeed, with so many therapeutic options available, the clinician must have a rational, risk stratified and feasible to approaching patients in relapse. This chapter provides an approach to therapy for the myeloma patient with relapsed and/or refractory disease. The detailed discussion of the data for the various treatment options in relapsed disease, including Stem Cell Transplantation, New Agents, and Biologic Therapy, is covered in subsequent chapters (see Chaps. 10–13). The purpose of this chapter is to provide an overall strategy for the management of relapsed refractory disease and to help guide clinicians in selecting the most appropriate therapy for their patient. This approach emphasizes the heterogeneity of both the disease and the patient.

AB - Despite tremendous advances in the initial management of patients with myeloma, now translating to at least a doubling of median overall survival in the last decade, this disease remains incurable in nearly all patients [1]. Although time to first relapse has been extended with superior induction, consolidation, and maintenance strategies, relapse is inevitable. With the emergence of many novel agents in the relapsed setting, options for providers and patients have dramatically increased. The optimal sequencing, combination, and dosing of these agents have yet to be determined. Indeed, with so many therapeutic options available, the clinician must have a rational, risk stratified and feasible to approaching patients in relapse. This chapter provides an approach to therapy for the myeloma patient with relapsed and/or refractory disease. The detailed discussion of the data for the various treatment options in relapsed disease, including Stem Cell Transplantation, New Agents, and Biologic Therapy, is covered in subsequent chapters (see Chaps. 10–13). The purpose of this chapter is to provide an overall strategy for the management of relapsed refractory disease and to help guide clinicians in selecting the most appropriate therapy for their patient. This approach emphasizes the heterogeneity of both the disease and the patient.

UR - http://www.scopus.com/inward/record.url?scp=84956564694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956564694&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-8520-9_9

DO - 10.1007/978-1-4614-8520-9_9

M3 - Chapter

AN - SCOPUS:84961335783

SN - 9781461485209

SN - 9781461485193

SP - 95

EP - 100

BT - Multiple Myeloma: Diagnosis and Treatment

PB - Springer New York

ER -